Ads
related to: ovarian cancer platinum resistant treatment reviews consumer reports
Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. [2] [5] [6] Recipients are selected for therapy based on an FDA ...
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
Immunotherapy's adoption in platinum-resistant ovarian cancer remains unsupported by studies, prompting a need for further investigation. [26] Nonetheless, evidence indicates that combining chemotherapy with the humanized anti- VEGF monoclonal antibody, bevacizumab, in the treatment of recurrent, persistent, or metastatic cervical cancer ...
Farletuzumab (MORAb-003) is a humanized monoclonal antibody [1] of IgG1/κ [2] which is being investigated for the treatment of ovarian cancer. [3] [4] This drug was developed by Morphotek, Inc. It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung ...
Olaparib in Patients With BRCA Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer: New Data Presented at ASCO CHICAGO--(BUSINESS WIRE)-- A retrospective subgroup analysis of a Phase II ...
OptumRx Awarded Platinum Honors by URAC for Best Practices in Health Care Consumer Empowerment and Protection Award recognizes My Medication Reminders as an Innovative Consumer Decision-Making ...
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
Ads
related to: ovarian cancer platinum resistant treatment reviews consumer reports